 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medison Pharma Announces Public Formulary Listing of QINLOCK (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment Medison Pharma...

Medison Pharma Announces Public Formulary Listing of QINLOCK (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) Treatment

In trading on Monday, shares of Deciphera Pharmaceuticals Inc (DCPH) touched a new 52-week low of 12.46/share. Thats a 10.30 share price drop, or -45.25% decline from the 52-week high...

Will Insiders Be Tempted To Buy More DCPH At The New 52-Week Low?

This is a signal that DCPH's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Deciphera Pharmaceuticals (DCPH, $12.88) Stochastic Oscillator left the oversold zone on September 22, 2023

SG Americas Securities LLC boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH  Free Report) by 815.1% in the second quarter, according to its most recent filing with...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Acquired by SG Americas Securities LLC

Unraveling the Factors That Could Limit Future GrowthRelated Stocks: DCPH...

Deciphera Pharmaceuticals Inc (DCPH): A Deep Dive into Its Performance Potential

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH  Get Free Report) have received a consensus recommendation of Moderate Buy from the eight ratings firms that are currently...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Consensus Recommendation of "Moderate Buy" by Analysts

This price move could indicate a change in the trend, and may be a sell signal for investors...

Deciphera Pharmaceuticals (DCPH, $13.42) price exceeded its 50-day Moving Average on September 15, 2023

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer...

Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Deciphera Pharmaceuticals (DCPH, $13.93) price exceeded its 50-day Moving Average on September 05, 2023

Russell Investments Group Ltd. lessened its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH  Free Report) by 55.1% during the first quarter, according to its most recent 13F filing...

Russell Investments Group Ltd. Cuts Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.

Watchers	3,233
52-Wk Low	$12.33
52-Wk High	$22.76

Market Cap	$1B
Volume (M)	281,976.00
52-Wk High	$22.76
52-Wk Low	$12.33

DCPH Deciphera Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals